Back to Journals » Advances in Genomics and Genetics » Volume 2

Mutational analysis of APOL1 in patients with Fechtner and Epstein syndromes: no evidence of a digenic etiology in MYH9-related disorders with renal disease

Authors McGredy M, Martignetti JA, Babcock

Received 12 April 2012

Accepted for publication 16 May 2012

Published 4 July 2012 Volume 2012:2 Pages 49—54


Review by Single-blind

Peer reviewer comments 2

Maxine McGredy,1 John A Martignetti,1–3 Melanie Babcock1

1Departments of Genetics and Genomic Sciences, 2Pediatrics, 3Oncological Sciences, Mount Sinai School of Medicine, New York, NY, USA

Abstract: Mutations in MYH9 result in a group of clinically overlapping autosomal dominant macrothrombocytopenia syndromes, collectively termed the MYH9-related disorders (MYH9RD). Intriguingly, three of these disorders, Fechtner, Alport-like, and Epstein syndromes, are associated with the additional clinical phenotype of glomerulosclerosis. Recently, an abundance of studies have demonstrated that the APOL1 gene, contiguous to MYH9, is associated with a form of kidney disease in individuals of African ancestry. Given these findings related to kidney disease arising in mutations in two contiguous genes, this study aimed to determine whether APOL1 mutations could also be present in patients with Fechtner (FTNS) and Epstein (EPS) syndromes. This study used sequence analysis to investigate a discrete discovery set of FTNS patients, but did not identify second hit mutations in APOL1.

Keywords: APOL1, MYH9, Fechtner syndrome, Epstein syndrome

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Synthesis, characterization, and antimicrobial activity of an ampicillin-conjugated magnetic nanoantibiotic for medical applications

Hussein-Al-Ali SH, El Zowalaty ME, Hussein MZ, Geilich BM, Webster TJ

International Journal of Nanomedicine 2014, 9:3801-3814

Published Date: 8 August 2014

Simple heuristics in over-the-counter drug choices: a new hint for medical education and practice

Silvia Riva, Marco Monti, Alessandro Antonietti

Advances in Medical Education and Practice 2011, 2:59-70

Published Date: 16 February 2011

Waiting for surgery from the patient perspective

Tracey Carr, Ulrich Teucher, Jackie Mann, Alan G Casson

Psychology Research and Behavior Management 2009, 2:107-119

Published Date: 14 October 2009

Selective p38α mitogen-activated protein kinase inhibitor attenuates lung inflammation and fibrosis in IL-13 transgenic mouse model of asthma

Jing Ying Ma, Satyanarayana Medicherla, Irene Kerr, Ruban Mangadu, Andrew A Protter, Linda S Higgins

Journal of Asthma and Allergy 2008, 1:31-44

Published Date: 16 November 2008

Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside

Ana Villegas, Fernando A Gonzalez, Leopoldo Llorente, Santiago Redondo

Biologics: Targets and Therapy 2008, 2:397-407

Published Date: 12 September 2008

Metabolism of ciclesonide in the upper and lower airways: review of available data

Ruediger Nave, Nigel McCracken

Journal of Asthma and Allergy 2008, 1:11-18

Published Date: 7 September 2008

Adverse effects of fullerenes on endothelial cells: Fullerenol C60(OH)24 induced tissue factor and ICAM-1 membrane expression and apoptosis in vitro

Monique P Gelderman, Olga Simakova, Jeffrey D Clogston, Anil K Patri, Sheena F Siddiqui, et al

International Journal of Nanomedicine 2008, 3:59-68

Published Date: 7 March 2008